Evidence map›Paper›PMID 25432660›Full record

Trial reportInternational journal of clinical oncology2015

Hepatic arterial infusion chemotherapy with fine-powder cisplatin and iodized-oil suspension in patients with intermediate-stage and advanced-stage (Barcelona Clinic Liver Cancer stage-B or stage-C) hepatocellular carcinoma: multicenter phase-II clinical study.

Haruyuki Takaki, Koichiro Yamakado, Masakatsu Tsurusaki, Taku Yasumoto, Yasutaka Baba, Yoshiaki Narimatsu, Masashi Shimohira, Masato Yamaguchi, Kunihiro Matsuo, Yoshitaka Inaba and 6 more

Abstract readClinical Trial, Phase IIMulticenter Study
PubMed Publisher
In one paragraph

Trial report in International journal of clinical oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 3 pooled it
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 3 syntheses or guidelines pooled it, 12 citations in OpenAlex.

  1. Guideline
  2. Guideline
  3. Guideline
  4. Review
  5. Review
  6. Efficacy and Safety of CalliSpheresOncology research · 2019
    Article
  7. Article
  8. Review
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 14 institutions in 1 country.

Haruyuki TakakiDepartment of Radiology, Mie University School of Medicine, Mie, Japan, takaki-h@clin.medic.mie-u.ac.jp.
Koichiro Yamakado
Masakatsu Tsurusaki
Taku Yasumoto
Yasutaka Baba
Yoshiaki Narimatsu
Masashi Shimohira
Masato Yamaguchi
Kunihiro Matsuo
Yoshitaka Inaba
Koji Mikami
Ryohei Watanabe
Norifumi Nishida
Hiroshi Anai
Hideaki Kakizawa
Shozo Hirota
Mie University · JPAichi Cancer Center · JPHiroshima University · JPHyogo Medical University · JPKagoshima University · JPKawasaki Municipal Hospital · JPKobe University · JPMatsuyama Shimin Hospital · JPNagoya City University · JPNara Medical University · JPOsaka City University · JPShimane University · JPSuita Municipal Hospital · JPToyonaka Municipal Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThis single-arm, multicenter, phase-II trial evaluated the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) using fine-powder cisplatin and iodized-oil suspension in patients with intermediate- and advanced-stage [Barcelona Clinic Liver Cancer (BCLC) stage-B and stage-C] hepatocellular carcinomas (HCCs).

methodsThe Institutional Review Board approved this study and patients provided written informed consent. Thirty-five patients (24 men and 11 women, mean 74 ± 6 years [range 60-87 years]) with BCLC stage-B (57 %, 20/35) or stage-C (43 %, 15/35) HCCs who were not candidates for other locoregional treatments were enrolled. HAIC was performed using a suspension of fine-powder cisplatin with a maximum dose of 65 mg/m(2) and iodized oil on demand. The primary endpoint was the response rate evaluated based on Response Evaluation Criteria in Solid Tumor (RECIST) and modified RECIST (mRECIST). Secondary endpoints were overall survival, progression-free survival, and safety.

resultsThe initial and best overall response rates at 4 weeks and 3 months, respectively, were 14 and 17 % based on RECIST, and 57 and 23 % based on mRECIST. The median overall and progression-free survival times were 18 and 4 months, respectively. The most frequent grade-3 or grade-4 adverse events were elevation of serum alanine (23 %) and aspartate aminotransferase (20 %), and thrombocytopenia (17 %).

conclusionThis HAIC provides promising therapeutic effects with acceptable safety to patients with intermediate-stage and advanced-stage HCCs.

Indexed as

AgedAged, 80 and overCarcinoma, HepatocellularCisplatinFemaleHepatic ArteryHumansInfusions, Intra-ArterialIodized OilLiver NeoplasmsMaleMiddle AgedNeoplasm StagingPowdersProspective StudiesTreatment OutcomeCisplatinIodized OilPowders

Identifiers

PMID25432660
OpenAlexW2024499428

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.